

PTOLSB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Raduction Act of 1995, no persons are required to respond to Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 1

10/626,155	
July 24, 2003	
Scott Beers	
-To be Assigned 1626	
Jo be Assigned G < War	neen
PRD 0022	ł
	July 24, 2003 Scott Beers To be Assigned 1626 To be Assigned 6 Swa

				U.S. PATENT DOCUMENTS		
		U.S. Patent Document		Name of Patentae or Applicant	Date of Publication	Pages, Columns, Lines,
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
	†					
	t^{-}					
	-					
<u> </u>	+-	 				
		<u> </u>		AND A THE PARKET PARKET		

		Foreign Patent Document Name of Patentee or					Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or relevant	
Examiner Initials	Cite No.1	Office ³	Number ⁴	KindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	figures appear	T	
						<u> </u>		 	
				_				╁╌	
	 	 -							
			 -						
	 	 	 						

···		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T²
Initials*	140.	BIEMOND, P. et al., "Superoxide production by polymorphonuclear leucocytes itn rheumatoid arthritis and osteoarthritis: in vivo inhibition by the antirheumatic drug piroxicam due to interference with the activation of the NADDH ovidese." Appels of the Rheumatic Diseases, 1986, pages 249-255.	
		TOOL II D. D. L. et al. "Call coloction for basic drugs" Intl. Pharmaceurics, 1300, pages 201-217.	
1		MIESEL, R. et al., "Antiinflammatory Effects of NADPH Oxidase Inhibitors," Immammation, 1999, pages 347	
	<u> </u>	MIESEL, R. et al., "Suppression of Inflammatory Athritis by Siimultaneous Inhibition of Nitric Oxide Symnase	
	-	HANCOCK, B. C., Characteristics and Significance of the Amorphous State in Pharmaceutical Systems, 5.	
1	<u> </u>	BIANCA, V.D. et al., "β-Amyloid Activates the O Forming NADPH Oxidase in Microgram WorldCyces, and	
Ž		BEGLEY, T.P. et al.), "The Biosynthesis of Nicotinamide Adenine Dinucleotides in Bacteria," <u>Vitamins & Hormones</u> , 2001/pages 103-119, Vol. 61.	

	Hollitoiles, 200 ly ppgod			
Examiner	/ IHM//	Date		() <
Charles /		// // // / Cons	sidered	<u> </u>

ed, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



101626,155

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DePARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

Application Number	To be Assigned	
Filing Date	July 24, 2003	
First Named Inventor	Scott Beers	
Group Art Unit	Net yet assigned 1512	
xaminer Name	Not yet assigned G. Show	,
Attomey Docket Number	PRD 0022	_

	,			U.S. PATENT DOCUMENTS		
}		U.S. Patent Do	cument		24 (2.15)	
Examiner	Cite		Kind Code ²	Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages
Initials	No.1	Number	(if known)	of Cited Document	mm-dd-yyyy	or relevant figures appear
						
	ļ	ļ				
					 	
	ļ	ļ	<u>-</u>			
	†				-	
	ļ			· · · · · · · · · · · · · · · · · · ·		
	<u> </u>		.			
······································					 	
					1	
			FORFIG	N PATENT DOCUMENTS		

		Foreign	Foreign Patent Document		Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	er Cite Office ³	Number ⁴ KindCode	Name of Patentee or Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	τ°	
X		wo	9504277	Sphinx Pharma Corp.	02-09-1995		
1		EP	0551662	Bayer AG	07-21-1993		
		EP	0171209	McNeilab Inc.	02-12-1986		
Y.		EР	0146271	McNellab Inc.	06-26-1985		
<u></u>		wo	0232435	AKL Technologies Ltd.	04-25-2002		

Signature AMM	Date Considered	X1/30105	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with and not considered. Include copy of this form with next communication to applicant.	MPEP 609. Drav	w line through citation if not in conformance	_

1 Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



SUBMISSION UNDER MPEP 609 D

Application Number 10/626,155
Filing Date July 24, 2003
First Named Inventor Beers, Scott
Group Art Unit Nut yet Assigned
Examiner Name National PRD-0022

166 shameen

Page 1 of 1

U.S. PATENT DOCUMENTS

U.S. Patent Document

U.S. Patent Document

U.S. Patent Document

U.S. Patent Document

Number

Kind Code Number

Number

Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMBENTS

FOREIGN PATENT DOCUMBENTS

Foreign Patent Document

Name of Patentse or Applicant of Cited Document

Name of Patentse or Applicant of Cited Document

Office³ Number⁴ KindCode³

Office³ Number⁴ KindCode³

Total Code Total Columns, Lines, where relevant passages or re

		FOREIGN	PAIENI	DOCUMEN	115		
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	Foreign Po	ntent Docum	ent KindCode ⁵	Pages, Columns, Lines, where relevant passages or relevant figures appear	T [©]
ļ,					+		
				 			
		OTHER PRIOR ART - N					
Examiner Cite No.1 Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published							T²
as		PCT International Search PCT/US 03/23140 which re	Report of	dated 07 U.S. Pate	/24/2002 1 ent Appin.	or PCT Appln. No. No. 10/626,155.	
	<u> </u>						
⊩ ——	\vdash						
<u> </u>	 						
 	 						
<u> </u>	 	 					

Examiner Signature	AAA	Mun	Date Considered	8/3.0/08	